Your SlideShare is downloading. ×
0
Endometrial Committee General Assembly report - David Miller
Endometrial Committee General Assembly report - David Miller
Endometrial Committee General Assembly report - David Miller
Endometrial Committee General Assembly report - David Miller
Endometrial Committee General Assembly report - David Miller
Endometrial Committee General Assembly report - David Miller
Endometrial Committee General Assembly report - David Miller
Endometrial Committee General Assembly report - David Miller
Endometrial Committee General Assembly report - David Miller
Endometrial Committee General Assembly report - David Miller
Endometrial Committee General Assembly report - David Miller
Endometrial Committee General Assembly report - David Miller
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Endometrial Committee General Assembly report - David Miller

653

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
653
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
14
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Endometrial Committee David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation Chair in Gynecologic Oncology Professor of Obstetrics & Gynecology University of Texas Southwestern Medical Center Dallas, Texas, U.S.A.
  • 2. Resected Endometrial • GOG0249: A Phase III Trial of Pelvic Radiation Therapy versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Cancer (23 Mar 2009) – RTOG
  • 3. Resected Endometrial • PORTEC 3: Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma – MaNGO, ANZGOG, NRCI, NCIC-CTG, NSGO
  • 4. Resected Endometrial • GOG258 (UC0704): A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Cancer (29 Jun 2009) – RTOG
  • 5. Study proposal Proposed new study exploring if the combination of RT and CT is superior to CT: After 4 - A Phase III intergroup trial on adjuvant therapy in radically NSGO HR 0.51 (95 % CI 0.29-0.91) p=0.02 0.77 0.87 0.000.250.500.751.00 197 187 164 149 118 87random = 1 187 175 153 130 106 75random = 0 Number at risk 0 1 2 3 4 5 analysis time random = 0 random = 1 CSS endometrioid carcinomas POOLED DATA Pooled survival data The combination of RT + CT is better than RT Results of previous studies: Thomas Hogberg, Lund Univ Hosp Oct 2009
  • 6. Radical surgery TAH+BSO±LA CTx4 Primary endpoint Overall survival (OS) CTx2 RT Randomization Main inclusion criteria a. Endometrioid carcinoma b. Stage 1C grade 3 c. Stage IIA grade 3 and MI≥50%, IIB d. Stage IIIA-C Radical surgery, LA recommended but optional Main exclusion criteria Serous or clear cell carcinoma IIIA with only pos fluid cytology CT :   Paclitaxel 175 mg/m2 , carboplatin AUC 5-6 (calculated) q 3 weeks N=1000 Proposed study Thomas Hogberg, Lund Univ Hosp Oct 2009
  • 7. Pelvic Recurrence • GOG0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic- only Recurrence of Carcinoma of the Uterine Corpus – RTOG, NCRI, SWOG
  • 8. EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY Interested Groups: ACRIN, AGO-AUST, AGO-OVAR,Interested Groups: ACRIN, AGO-AUST, AGO-OVAR, ANZGOG?, DUTCH GOG, EORTC, GEICO, GINECO,ANZGOG?, DUTCH GOG, EORTC, GEICO, GINECO, JGOG, MANGO, MITO, NCRI, NSGO, SWOGJGOG, MANGO, MITO, NCRI, NSGO, SWOG
  • 9. Schema Sample size: Approximately 460 patients Arm 2: medroxy progesterone 200 mg or megestrol 160 mg (as per local practice) po daily Chemotherapy options Survival follow-up Disease progression Imaging q 8 weeks Arm 1: ridaforolimus 40 mg po days 1-5 each week R A N D O M I Z E Women with recurrent or metastatic endometrial cancer 1-2 Prior Chemotherapy
  • 10. Carcinosarcoma GOG0261: Randomized Phase III Trial of Carboplatin plus Paclitaxel versus Ifosfamide plus Taxol in Patients with Advanced, Persistent or Recurrent Carcinosarcoma NCRI, GINECO, JGOG, RTOG
  • 11. GTN • Charge from the Executive • RFP • ISSTD
  • 12. GTD Concepts • Hydatidiform Mole Registry (Quinn) • Pulse Act-D vs. 8 day MTX for Low Risk GTN

×